18
Management
Table 5. Characteristics of Common Lipid-Lowering
Medications to Treat Dyslipidemia*
Class Mechanism of Action Medications
Typical Dose
Range
Triglyceride-Lowering Medications
Fibrates Stimulates PPAR-alpha,
which activates lipoprotein
lipase and reduces
apolipoprotein C-III
production; increases
lipolysis and elimination of
TG-rich particles
Fenofibrate 40–200 mg
Fenofibric acid 35–135 mg
Gemfibrozil 600 mg
Omega-3 fatty
acids
Reduces hepatic VLDL TG
synthesis and/or secretion;
enhances TG clearance from
circulating VLDL; other
mechanisms are possible
Icosapent ethyl 4 g
Omega-3 acid
ethyl esters
4 g
(cont'd)
